Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GABRP | O00591 | 3/20 | 0.40 |
| ▸ | GABRD | O14764 | 3/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.40 |
| ▸ | GABRE | P78334 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10576552 | 0.83 | MAPK1 (0.39) | MAPK1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL22533879 | 0.80 | CHEK2 (0.49) | ALDH1A1HPGDLMNARAB9ASMN1; SMN2 | |
| SCHEMBL6301028 | 0.75 | MAPK1 (0.41) | MAPK1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL22533971 | 0.74 | CTSA (0.46) | MAPK1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL29424799 | 0.74 | CTSA (0.46) | MAPK1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL6300995 | 0.73 | KDM4E (0.44) | MAPK1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5032566 | 0.70 | HSP90AA1 (0.53) | MAPK1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL30829502 | 0.70 | NR4A2 (0.43) | MAPK1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL17514134 | 0.70 | MAPK1 (0.42) | MAPK1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL18725355 | 0.69 | SMN1; SMN2 (0.46) | MAPK1KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911469-B2 | Sulfonamide compounds and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| US-6890934-B2 | Sulfonamide compounds and uses thereof as medicines | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-10 | — | — | US | disclosed |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| US-20030171396-A1 | Sulfonamide compounds and uses thereof as medicines | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-09-11 | — | — | US | disclosed |
| US-6573274-B1 | Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-07-25 | — | — | US | disclosed |
| US-6348474-B1 | COMPOUNDS AS ANTIDIABETIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-1136492-A1 | SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-09-26 | — | — | EP | disclosed |
| EP-0995742-A1 | SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | PDE2A, PDE3A, PDE12 | MAPK1 921/4885KDM4E 1305/4885ALDH1A1 570/4885 |
| US-20030171396-A1 | Sulfonamide compounds and uses thereof as medicines | PDE2A, PDE3A, PDE5A | MAPK1 434/4885KDM4E 1599/4885ALDH1A1 476/4885 |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | PDE2A, PDE3A, PYGM | MAPK1 1425/4885KDM4E 935/4885ALDH1A1 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.